180 related articles for article (PubMed ID: 23063577)
21. Acute cardiac failure after sunitinib.
Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
[No Abstract] [Full Text] [Related]
22. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
23. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
Baldazzi V; Tassi R; Lapini A; Santomaggio C; Carini M; Mazzanti R
Urol Oncol; 2012 Sep; 30(5):704-10. PubMed ID: 20884255
[TBL] [Abstract][Full Text] [Related]
24. Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma.
Oh JJ; Hong SK; Joo YM; Lee BK; Min SH; Lee S; Byun SS; Lee SE
Jpn J Clin Oncol; 2012 Apr; 42(4):314-7. PubMed ID: 22323554
[TBL] [Abstract][Full Text] [Related]
25. Rectal perforation after two years of treatment with sunitinib for metastatic kidney cancer.
Bladé JS; Bourgouin S; Romeo É; Boudin L; de Jauréguiberry JP
Presse Med; 2014 Nov; 43(11):1293-5. PubMed ID: 24999082
[No Abstract] [Full Text] [Related]
26. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
27. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.
Del Fabbro E; Dev R; Cabanillas ME; Busaidy NL; Rodriguez EC; Bruera E
J Chemother; 2012 Aug; 24(4):221-5. PubMed ID: 23040687
[TBL] [Abstract][Full Text] [Related]
28. Severe exacerbation of Crohn's disease during sunitinib treatment.
Boers-Sonderen MJ; Mulder SF; Nagtegaal ID; Jacobs JF; Wanten GJ; Hoentjen F; van Herpen CM
Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):234-6. PubMed ID: 24025975
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
31. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
Tsai KY; Yang CH; Kuo TT; Hong HS; Chang JW
J Clin Oncol; 2006 Dec; 24(36):5786-8. PubMed ID: 17179114
[No Abstract] [Full Text] [Related]
32. Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma.
Gilabert M; Provansal M; Cappiello M; Walz Y; Salem N; Tarpin C; Brunelle S; Thomassin J; Gravis G
Br J Cancer; 2013 Oct; 109(7):1750-4. PubMed ID: 24045668
[TBL] [Abstract][Full Text] [Related]
33. Home blood-pressure monitoring in patients receiving sunitinib.
Azizi M; Chedid A; Oudard S
N Engl J Med; 2008 Jan; 358(1):95-7. PubMed ID: 18172185
[No Abstract] [Full Text] [Related]
34. [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
Sire M; Wallerand H; Kilkoski F; Grenier N; Ferrière JM; Ravaud A
Bull Cancer; 2008 Sep; 95(9):813-20. PubMed ID: 18829413
[TBL] [Abstract][Full Text] [Related]
35. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
36. Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?
Park I; Park K; Park S; Ahn Y; Ahn JH; Choi HJ; Jeong IG; Song C; Hong JH; Kim CS; Ahn H; Lee JL
Clin Genitourin Cancer; 2013 Sep; 11(3):276-82. PubMed ID: 23332873
[TBL] [Abstract][Full Text] [Related]
37. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
[TBL] [Abstract][Full Text] [Related]
38. Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
Daniels GH
Clin Endocrinol (Oxf); 2009 Sep; 71(3):455. PubMed ID: 19138312
[No Abstract] [Full Text] [Related]
39. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
Motzer RJ; Hutson TE; McCann L; Deen K; Choueiri TK
N Engl J Med; 2014 May; 370(18):1769-70. PubMed ID: 24785224
[No Abstract] [Full Text] [Related]
40. Pazopanib versus sunitinib in renal cancer.
Casper J; Schumann-Binarsch S; Köhne CH
N Engl J Med; 2013 Nov; 369(20):1969. PubMed ID: 24224638
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
